

**Structural Hippocampal Damage Following Anti-N-Methyl-D-Aspartate Receptor Encephalitis**  
**Supplemental Information**

**Table S1. Patient characteristics.**

	Sex	Age	Acute Clinical MRI Studies	Time between Disease Onset and Imaging Study [months]	IgG Titer at Imaging		Seizures	Neurotoxic Drugs
					CSF	Serum		
1	F	36	normal	26	32	100	GM	cyclophosphamide
2	F	23	normal	42	10	32	single GM	no
3	F	32	normal	40	320	neg.	GM, focal seizures	no
4	M	28	normal	53	3	1	GM	no
5	F	45	normal	40	32	neg.	focal seizures	no
6	F	30	small WM lesions left insula	66	neg.	neg.	yes	no
7	F	38	multiple WM lesions	72	32	neg.	single GM	methotrexate
8	F	26	normal	37	neg.	neg.	no	no
9	F	22	normal	25	32	1000	GM	no
10	F	19	singular left frontal WM lesion	15	10	10	single GM	no
11	F	24	normal	16	neg.	10	no	no
12	F	19	singular left frontal WM lesion	41	10	neg.	no	no
13	F	21	normal	14	10	100	yes	no
14	F	24	normal	20	3	neg.	GM	no
15	F	25	normal	44	1	neg.	no	no
16	F	18	normal	33	n.d.	1000	GM	azathioprine
17	F	22	two small frontal WM lesions	11	neg.	neg.	no	no
18	M	42	normal	47	n.d.	neg.	GM	no
19	F	21	normal	14	1	32	GM	mycophenolate mofetil

	Sex	Age	Acute Clinical MRI Studies	Time between Disease Onset and Imaging Study [months]	IgG Titer at Imaging		Seizures	Neurotoxic Drugs
					CSF	Serum		
20	M	33	normal	19	10	100	single GM	no
21	F	40	single, transient left frontal WM lesion	9	neg.	neg.	GM	cyclophosphamide
22	F	32	normal	42	neg.	neg.	focal seizures	azathioprin
23	F	18	normal	10	3	10	GM	no
24	F	30	transient T2 hyperintense lesions right precentral gyrus, left postcentral gyrus, left thalamus	72	neg.	neg.	GM series and focal seizures	cyclophosphamide
25	F	30	normal	19	3	32	GM series	cyclophosphamide
26	F	15	normal	4	n.d.	100	focal seizures	no
27	F	25	bilateral medial temporal lobe hyperintensities	16	10	32	yes	no
28	F	21	normal	4	10	100	GM	no
29	M	67	normal	1	1	100	yes	no
30	F	18	normal	4	100	10	yes	no
31	F	16	normal	2	32	10	yes	no
32	F	17	normal	3	10	100	yes	no
33	F	22	normal	7	32	320	GM	cyclophosphamide
34	F	25	normal	34	n.d.	10	yes	cyclophosphamide, bortezomib, methotrexate
35	F	32	normal	51	neg.	100	non-convulsive status, GM seizures	cyclophosphamide
36	F	18	normal	8	32	1000	yes	etoposid, cisplatin, bleomycin
37	F	35	frontal and temporal WM lesions	4	3	100	no	no
38	F	18	normal	43	3	10	no	no
39	F	42	multiple small WM lesions	25	3	neg.	no	no
40	F	45	normal	21	n.d.	100	no	no

CSF, cerebrospinal fluid; GM, grand mal seizure; F, female; M, male; n.d., not detected; neg., negative; WM, white matter.

**Table S2. Analysis of whole hippocampal volume using FSL FIRST.**

	Patients		Controls		<i>df</i>	<i>F</i>	<i>p</i> Value
	Mean	SEM	Mean	SEM			
<b>Left</b>							
Hippocampus	3626.45	87.73	3905.84	89.46	1	4.501	0.038
<b>Right</b>							
Hippocampus	3747.48	75.05	3998.84	95.94	1	4.279	0.043